DEXCOM INC (DXCM)

Dexcom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for managing diabetes and metabolic health, used by patients, caregivers and clinicians worldwide. It received FDA approval for and commercialized its first product in 2006. Its CGM systems replace routine finger-stick testing by sending glucose readings every five minutes to a receiver or compatible mobile device, with customizable alerts, including a predictive low alert. The company's technology platform rests on biomaterials, membrane systems, electrochemistry and low-power microelectronics, which convert a very small electrical signal from a glucose-specific enzyme reaction into glucose values.

Current products include the Dexcom G7, launched in 2023 and cleared in the U.S. for people with diabetes aged two and older, and the G7 15 Day, launched in late 2025 for adults, with a 15.5-day wear period. Both are FDA Class II integrated CGM systems cleared through the 510(k) process. The G6 is being transitioned to the G7 platform by the end of 2026. In Europe the company offers Dexcom ONE+, and the older Dexcom ONE is expected to be phased out by the end of 2026. Stelo, launched in August 2024, is an over-the-counter biosensor for adults with prediabetes and Type 2 diabetes who do not use insulin, and is the first of its kind in the U.S. Software offerings include Dexcom Clarity cloud reporting, the Share and Follow remote monitoring apps, which let up to ten followers view data, and a Real-Time API that lets authorized third-party developers integrate CGM data into their apps and devices. The company also has collaborations to integrate its sensors with insulin pumps, smart pens and automated insulin delivery systems, and with organizations running Type 2 diabetes programs.

The core market is people with Type 1 and Type 2 diabetes who use insulin, plus certain non-insulin users who struggle with hypoglycemia. The company also sees a growing opportunity among people with Type 2 diabetes who do not use insulin, which it estimates at more than 25 million people in the U.S., and among people seeking to optimize metabolic health. It plans to pursue pregnancy, prediabetes, obesity and hospital indications. Most revenue has come from the United States, but operations have expanded to other markets in North America, Africa, Asia Pacific, Europe, Latin America and the Middle East. Coverage comes from Medicare, Medicaid in most states and commercial insurers, subject to eligibility criteria. Dexcom sells through a direct sales and marketing effort and key distribution arrangements, and seeks broad reimbursement from private payors and national health systems.

The G7 has CE Mark approval, and the G6 has CE Mark approval for the European Union and other countries that recognize it. The text does not identify suppliers, manufacturing sites, competitors or headquarters. Its strategy centers on maintaining its technology platform, supporting innovation through integration partnerships, expanding to new patient populations and care settings, and providing customer support and high safety and quality standards. It is also developing future products aimed at improved performance and intelligent insulin administration.